- Home
- News
- canada new brunswick
- diabetes
Refine by
Diabetes Articles & Analysis
455 news found
Bremen, Germany – May 4, 2026 — Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at EWMA-DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany.This year EWMA, The European Wound Management Association meeting, is held in ...
ByKerecis
Charlotte, North Carolina – April 7, 2026. Kerecis will highlight its intact fish-skin platform and new clinical data at SAWC Spring 2026, taking place April 8–11 at the Charlotte Convention Center. The company will showcase intact fish-skin grafts alongside Biatain wound dressings and discuss expanded multi-specialty adoption. Booth presence is at Booth 1508; clinical insights and trial results ...
ByKerecis
Creative Proteomics, a leader in proteomics and metabolomics services, has officially launched its innovative Central Carbon Metabolism (CCM) Analysis Service, designed to transform the study of cellular energy dynamics and metabolic pathways in both health and disease. This groundbreaking service arrives at a crucial time when understanding cellular metabolism is essential for advancing ...
Protheragen-ING, a distinguished name in the realm of pharmaceutical innovation, has proudly announced its most sought-after Active Pharmaceutical Ingredients (APIs). Known for offering tailored technical research and development services to researchers globally, Protheragen-ING emphasizes its commitment to pioneering advancement in pharmaceutical sciences. Among the top APIs highlighted are ...
We’re starting the week by welcoming Rebecca Warfvinge and João Vieira to the BPC team! Both join us as Technical Sales Scientists, bringing research expertise that will help our customers advance their work. Rebecca holds a master’s degree in biomedicine and has since conducted research for several years at Lund University in leukemia, where she used single-cell methods to ...
Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. Diabetes mellitus, a chronic condition characterized by elevated blood ...
Obesity is a metabolic condition resulting from an imbalance between the energy consumed and the energy expended. This is often caused by an increase in the intake of calorie-dense foods and a decrease in physical activity, leading to an abnormal build-up of fat. Such fat accumulation can have serious health consequences, raising the risk of chronic diseases like cardiovascular conditions, ...
This year Protheragen-ING has extended its portfolio of Active Pharmaceutical Ingredients (APIs) to include several hundred new varieties, catering to a broad spectrum of therapeutic needs such as anti-tumor, hypoglycemic, antipsychotic, bronchiectasis, and antihypertensive treatments. Such growth represents Protheragen-ING’s commitment to support researchers worldwide in their quest of ...
Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into disease mechanisms and potential treatment options. ...
Creative Enzymes, a leading provider of high-quality enzymes and biochemicals, is proud to announce the addition of Semaglutide to its comprehensive product portfolio. This novel glucagon-like peptide-1 (GLP-1) receptor agonist has generated significant excitement within the pharmaceutical and life sciences industries due to its remarkable efficacy in managing type 2 diabetes. Semaglutide ...
Huateng Pharma, a distinguished provider of premium pharmaceutical intermediates, proudly unveils its latest breakthrough: Semaglutide Side Chain. This groundbreaking addition to Huateng Pharma's esteemed portfolio signifies a remarkable leap forward in pharmaceutical innovation, showcasing a diverse array of compounds including AEEA-AEEA (CAS NO.: 1143516-05-5), SNAC (CAS NO.: 203787-91-1), ...
Advancements in drug delivery technology have paved the way for more efficient and targeted treatment options. Among these innovations is the development of coated microneedle preparation technology, which has shown promising results in delivering novel drugs to patients. CD formulation involves coated microneedles with specific drug compounds, allowing for controlled and sustained drug delivery. ...
CD BioSciences, a US-based CRO serving the global life science research community, has announced the launch of its new services to study the Mechanistic Target of Rapamycin (mTOR) in diabetes and metabolism research. The mechanistic Target of Rapamycin is a serine/threonine protein kinase that is inhibited by rapamycin, a bacterial compound originally isolated from Easter Island soil that ...
We are delighted to welcome Roczen to the community of healthcare organisations leveraging Vantage Software! We look forward to working together and helping them deliver exceptional care and support to those living with chronic conditions. Book a Free Demo ...
Huateng Pharma proudly announces the launch of a groundbreaking suite of anti-diabetes intermediates, featuring key compounds such as Canagliflozin, Dapagliflozin, Empagliflozin, and Semaglutide. Emphasizing the potential impact on diabetes drug development, Huateng Pharma's Research and Development Director expressed enthusiasm, stating, "Our new line of anti-diabetes intermediates represents a ...
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to Eylea (aflibercept 2 mg) at fixed 8-weekly dosing over two years Patients assigned to a 16-week dosing regimen at baseline received a mean of 7.8 injections (6 fewer than Eylea) Safety profile of aflibercept 8 mg in diabetic macular edema (DME) remains comparable to Eylea ...
ByBayer AG
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...
ByBayer AG
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) QUASAR is expected to enroll around 800 patients in 27 ...
ByBayer AG
Alfa Chemistry, a leading pharmaceutical supplier, has recently announced the addition of three new APIs to its full-ranged product catalog, i.e., tofacitinib citrate, tamoxifen citrate, and epalrestat. These new products are introduced to meet the growing demands of the pharmaceutical market. Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic ...
The best CO2 fractional laser machine is a laser treatment for spots, wrinkles, scars and warts, which is usually a type of laser that stimulates the skin tissue through the focused energy emitted by the gas laser. Which not only blasts the melanin particles on the surface instantly, but also stimulates the collagen tissue underneath the skin to gradually repair the skin. It also stimulates the ...